EGFR and non-small cell lung carcinoma: It took another 5 years, before the landmark IPASS trial (16) and several other pivotal phase III randomized studies (17, 18) demonstrated the importance of EGFR mutations as a critical driver in NSCLC, and established EGFR TKIs as the standard-of-care first-line therapy for this subgroup of patients.